AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Travere Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SL72C5
50.08▼ 2.35 (-4.48%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
52.43
Day's Range
49.78 – 52.22
52-Week Range
22.59 – 68.73
Volume
2.3M
Avg Volume
1.8M
Share Statistics
Shares Outstanding
Employees
497
Exchange
XNAS
Listed
2003-07-23
Share count as of July 30, 2026

Travere Therapeutics, Inc. Common Stock (TVTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Travere Therapeutics, Inc. Common Stock (TVTX)
What is Travere Therapeutics, Inc. Common Stock's Market Cap?
Travere Therapeutics, Inc. Common Stock's Market Cap is $4.7B, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's Enterprise Value?
Travere Therapeutics, Inc. Common Stock's Enterprise Value is $4.6B, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's Price / Sales?
Travere Therapeutics, Inc. Common Stock's Price / Sales is 8.0×, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's EV / Revenue?
Travere Therapeutics, Inc. Common Stock's EV / Revenue is 7.8×, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's EV / EBITDA?
Travere Therapeutics, Inc. Common Stock's EV / EBITDA is 200.9×, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's Revenue (TTM)?
Travere Therapeutics, Inc. Common Stock's Revenue (TTM) is $591.3M, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's Net Income (TTM)?
Travere Therapeutics, Inc. Common Stock's Net Income (TTM) is -$43.5M, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's EBITDA?
Travere Therapeutics, Inc. Common Stock's EBITDA is $22.9M, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Travere Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.46, based on as-reported figures from SEC (XBRL) filings.
What is Travere Therapeutics, Inc. Common Stock's EBITDA Margin?
Travere Therapeutics, Inc. Common Stock's EBITDA Margin is 3.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TVTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Total revenue
YoY growth+48.2%+55.6%+73.4%+162.1%
Operating expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Royalty expense——
Total operating expenses
% of revenue97.7%129.0%125.0%84.9%
Operating income (loss)
% of revenue2.3%-29.0%-25.0%15.1%
Other (expense) income, net:
Interest income
Interest expense
Other (expense) income, net
Inducement expense———
Total other (expense) income, net
Loss from continuing operations before income tax
Income tax benefit (provision) on continuing operations
Loss from continuing operations, net of tax
Loss from discontinued operations, net of tax
Net loss
% of revenue-20.5%-29.2%2.1%15.6%
Net loss per common share, basic (in dollars per share)
Net loss per common share, diluted (in dollars per share)